"Compassionate Use" Programmes
"Compassionate Use" was introduced into the German legislation with the 14th amendment of the German Medicinal Product Act (AMG) and modified by the amendment of the German Medicinal Product Act in July 2009. Section 21 sub-section 2 No 6 of the German Medicinal Product Act provides (Non-official translation):
"(2) A marketing authorisation (Zulassung) shall not be required for medicinal products which: [...]
6. are made available free of charge under the conditions specified to in Article 83 of Regulation (EC) No. 726/2004 for administration to patients with a seriously debilitating disease or whose disease is life-threatening, and who cannot be treated satisfactorily with an authorised medicinal product; this applies equally to medicinal products which do not fall under the categories stipulated in Article 3 first or second paragraph of Council Regulation (EC) No. 726/2004; rules of procedure shall be specified in an ordinance pursuant to Section 80. [...]"
The Ordinance on Medicinal Products for Compassionate Use (AMHV) pursuant to Section 80 of the German Medicinal Product Act was published on 21 July 2010 in the Federal Law Gazette 2010 part I No 37 and came into force on 22 July 2010. A non-offical translation is available for download.
The Ordinance on Medicinal Products for Compassionate Use (AMHV) came into force on 22 July 2010. The Ordinance on Medicinal Products for Compassionate Use introduces the confirmed notification procedure for compassionate use programmes. BfArM and PEI are now the competent authorities for the confirmed notification procedure of compassionate use programmes according to their responsibilities as regulated by Section 77 of the German Medicinal Product Act. Since 23 July 2010 the commencement of any new compassionate use programme requires a confirmation of notification by the higher federal competent authority (in this case, BfArM).
BfArM has published a guide on submitting compassionate use programmes and a notification form
Compassionate use notifications should be submitted in paper and CD-ROM/DVD to the following address:
Federal Institute for Drugs and Medical Devices (BfArM)
Kurt-Georg-Kiesinger Allee 3
For more information feel free to contact the BfArM at email@example.com
The Ordinance on Medicinal Products for Compassionate Use is only applicable for compassionate use programmes, i.e. cohort programmes which are intended for a group of patients (cohort compassionate use). A 'named patient compassionate use' is not in the scope of the notification procedure as laid down in the Ordinance on Medicinal Products for Compassionate Use. Please refer to the following flow chart for the decision on compassionate use:
Current Compassionate Use Programmes confirmed by BfArM
A list of currently confirmed and active compassionate use programmes is available here:
Information provided by the EMA
The EMA has published CHMP opinions on "compassionate use" programmes as well as a "Question and Answer" document on "compassionate use" programmes: